Physician profile
Joseph P Langshaw
NPI 1548226129
$879,042.30
in general payments reported to CMS, 2019-2025
20 companies · $236K in 2025
The $236K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74K · 2022: $159K · 2023: $171K · 2024: $240K · 2025: $236K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $458K · Travel and Lodging: $167K · Food and Beverage: $14K · Consulting Fee: $6,323 · Education: $69.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $458,052.75 |
| Travel and Lodging | $167,332.55 |
| Food and Beverage | $14,256.65 |
| Consulting Fee | $6,322.50 |
| Education | $69.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530,595.17 | 2021-2025 | |
| Ucb, INC. | $159,315.88 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $72,017.58 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $58,081.09 | 2021-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $44,691.43 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $10,770.86 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $967.26 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $765.68 | 2021-2024 | |
| Genzyme Corporation | $649.45 | 2021-2025 | |
| Dermavant Sciences, INC. | $267.41 | 2022-2024 | Vtama |
| Pfizer INC. | $185.74 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $163.69 | 2022-2023 | Ilumya |
| Leo Pharma INC. | $148.07 | 2022-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $145.74 | 2021-2024 | Targretin, Siliq, Jublia |
| Regeneron Healthcare Solutions, INC. | $81.72 | 2022-2024 | Libtayo, Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $64.97 | 2023 | |
| Galderma Laboratories, L.P. | $62.41 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $23.85 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.86 | 2023 | |
| Botanix Sb INC | $21.44 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Langshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.